4565 — Nxera Pharma Co Cashflow Statement
0.000.00%
Last trade - 00:00- ¥80bn
- ¥115bn
- ¥29bn
Annual cashflow statement for Nxera Pharma Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1,622 | 433 | 1,078 | -10,680 | -4,662 |
| Depreciation | |||||
| Non-Cash Items | -972 | 6,711 | 3,565 | 1,841 | -792 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2,672 | -1,327 | 3,964 | 1,088 | -6,248 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 4,672 | 7,095 | 9,952 | -5,273 | -7,718 |
| Capital Expenditures | -105 | -201 | -303 | -851 | -1,537 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -45 | 479 | 1,346 | -62,940 | -3,226 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -150 | 278 | 1,043 | -63,791 | -4,763 |
| Financing Cash Flow Items | -597 | -191 | -4,681 | -27 | -2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 20,278 | 11,123 | -4,887 | 48,329 | -6,854 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 24,633 | 20,079 | 6,470 | -17,492 | -16,797 |